The results showed that hepatitis and pneumonia were occasionally observed in the PD-1 group, but almost never in the PD-1+SMI group (Additional file 1: Fig. S1A and B), indicating that the combination of SMI and PD-1 inhibitors reduced adverse reactions. The gene discussed is PDCD1; the disease is pneumonia.